ω-3 Polyunsaturated Fatty Acids Up-regulate the Expression of 15-PGDH by Inhibiting miR-26a and miR-26b in Human Cholangiocarcinoma Cells

Lu Yao¹, Chang Han¹, Kyoungsub Song¹, Jinqiang Zhang¹, Kyu Lim², and Tong Wu¹

1. Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA 70112
2. Department of Biochemistry, College of Medicine, Cancer Research Institute and Infection Signaling Network Research Center, Chungnam National University, Daejeon, Korea

Address correspondence to:

Tong Wu, M.D., Ph.D.
Department of Pathology and Laboratory Medicine
Tulane University School of Medicine
1430 Tulane Avenue, SL-79
New Orleans, LA 70112
Tel: 504-988-5210
Fax: 504-988-7862
E-mail: twu@tulane.edu

Running Title: ω-3 PUFAs up-regulate the expression of 15-PGDH in cholangiocarcinoma

Key words: ω-3 PUFA, 15-PGDH, miR-26, cholangiocarcinoma

This work is supported by grants from NCI and NIDDK (R01 CA134568, R01 CA102325, R01 CA106280, and R01 DK077776 to T.W.).

No conflict of interest to disclose

Contributions: T.W. conceived the project and L.Y., C.H and T.W. designed the experiments; L.Y. performed experiments and analyzed the data; K.S. and J.Z. assisted experiments; K.S., J.Z. and K. L. and C.H. helped with data discussions; L.Y. and T.W. wrote the paper; T.W. obtained funding.
ABSTRACT

Prostaglandins E₂ (PGE₂) is a pro-inflammatory and pro-tumorigenic lipid mediator that promotes cholangiocarcinoma growth in vitro and in vivo. The NAD⁺-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) catalyzes the oxidation of the 15(S)-hydroxyl group of PGE₂, leading to PGE₂ inactivation. Therefore, induction of 15-PGDH expression may represent a new strategy for the treatment of human cholangiocarcinoma. Here we report that ω-3 polyunsaturated fatty acids (ω-3 PUFAs) up-regulate the expression of 15-PGDH by inhibiting miR26a and miR26b and these effects contribute to ω-3 PUFA-induced inhibition of cholangiocarcinoma growth. Treatment of human cholangiocarcinoma cells (CCLP1 and TFK-1) with ω-3 PUFA (DHA) or transfection of these cells with the Fat-1 gene (encoding Caenorhabditis elegans desaturase which converts ω-6 PUFA to ω-3 PUFA) significantly increased 15-PGDH protein level in cholangiocarcinoma cell lines. On the other hand, DHA treatment or Fat-1 overexpression had little effect on 15-PGDH promoter activity. Human cholangiocarcinoma cells treated with DHA or transfected with Fat-1 expression vector showed reduction of miRNA26a and miRNA26b (both miRNAs target 15-PGDH mRNA thus inhibiting 15-PGDH translation). Consistent with these findings, we observed that overexpression of miR26a or miR26b decreased 15-PGDH protein, reversed ω-3 PUFA-induced accumulation of 15-PGDH protein, and prevented ω-3 PUFA-induced inhibition of cholangiocarcinoma cell growth. Knockdown of 15-PGDH also attenuated ω-3 PUFA-induced inhibition of tumor cell growth. We observed that ω-3 PUFA suppressed miRNA26a and miRNA26b by inhibiting c-myc, a transcription factor that co-regulates gene clusters comprising of miR-26a/b with their host genes CTDSPs. Accordingly, overexpression of c-myc enhanced the expression of miRNA26a/b and prevented ω-3 PUFA-induced inhibition of tumor cell growth. Taken together, our results provide novel evidence for induction of 15-PGDH via suppression of miR26a/b in human cholangiocarcinoma cells and suggest ω-3 PUFA as potential agent for the treatment of human cholangiocarcinoma.
INTRODUCTION

Cholangiocarcinoma (CCA) is a highly malignant cancer of the biliary tract with poor prognosis(1-12). The incidence and mortality of cholangiocarcinoma is rising worldwide and currently there is no effective chemoprevention or treatment. The tumor often arises from background conditions that cause long-standing inflammation, injury and reparative biliary epithelial cell proliferation, such as primary sclerosing cholangitis (PSC), clonorchiasis, hepatolithiasis or complicated fibropolycystic diseases. Intrahepatic cholangiocellular carcinoma is also associated with hepatitis C viral infection and liver cirrhosis secondary to other nonbiliary causes. The carcinogenic processes involve a series of sequential events including chronic inflammation, cholangiocyte proliferation, dysplasia and ultimately malignant transformation.

Consistent with the strong association between bile duct chronic inflammation and cholangiocarcinogenesis, compelling evidence(10, 13-28) have shown that mediators of inflammation, such as prostaglandins (PGs), play an important role in cholangiocarcinogenesis. For example, elevated expression of COX-2 has been documented in CCA cells and pre-cancerous bile duct lesions but not in normal bile duct epithelial cells(21-25); the expression of COX-2 is induced by proinflammatory cytokines as well as bile acids(29, 30). Overexpression of COX-2 in human CCA cells enhances PGE$_2$ production and promotes tumor growth, whereas depletion of COX-2 reduces PGE$_2$ production and prevents growth(14, 15). PGE$_2$ treatment is known to increase CCA cell growth and prevent apoptosis(13-15, 26-28). Accordingly, inhibition of COX-2 by molecular and pharmacological approaches prevents the growth and invasion of CCA cells in vitro and in animal models(10, 14, 15, 22, 25, 27, 28). These findings
provide important preclinical evidence for targeting COX-2 in prevention and treatment of human CCA. However, as some COX-2 inhibitors are known to be associated with increased cardiovascular side effect(31-34), there is an urgent and practical need to identify COX-2 downstream target for effective anti-CCA therapy with fewer side effects.

The amount of biologically active PGE$_2$ in the inflammatory and tumor microenvironment is regulated by the balance between PGE$_2$ synthesis and degradation. While previous studies have focused on the role of COX-2 in carcinogenesis, the role of PGE$_2$ degradation enzyme, the NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH), has not been recognized until recently. 15-PGDH catalyzes oxidation of the 15(S)-hydroxyl group of PGE$_2$, converting PGE$_2$ into 15-keto-PGE$_2$; this enzymatic reaction leads to reduction of the pro-inflammatory and pro-tumorigenic PGE$_2$(35). Indeed, accumulating evidence suggests that 15-PGDH is an important tumor suppressor in a number of human cancers including cholangiocarcinoma(36).

While the pro-inflammatory and pro-carcinogenic PGs are synthesized from arachidonic acid (AA), a ω-6 PUFA; this process is competitively inhibited by ω-3 polyunsaturated fatty acids (ω-3 PUFAs). The lipid mediators derived from ω-6 and ω-3 PUFA are metabolically distinct and often have opposing physiological and pathological functions; for example, ω-6 PUFA-derived eicosanoids tend to promote inflammation and carcinogenesis, while ω-3 PUFA-derived lipid mediators largely inhibit inflammation and prevent carcinogenesis (or less promotional for inflammation and proliferation). In the current study, we report that ω-3 PUFA (but not ω-6 PUFA) up-regulates the expression of 15-PGDH by inhibiting miR26a and miR26b in human cholangiocarcinoma cells. We show that 15-PGDH is a bona fide target of miR26a
and miR26b. Our findings provide novel evidence for ω-3 PUFA-regulated miR26a/b and 15-PGDH cascade and support ω-3 PUFA as a non-toxic therapeutic agent for the treatment of human cholangiocarcinoma.
MATERIALS AND METHODS

Materials. Docosahexaenoic acid (DHA) and arachidonic acid (AA) were purchased from Cayman Chemical (Ann Arbor, MI). miR26a and miR26b lentiviral particles were purchased from GeneCopoeia (Rockville, MD). 15-PGDH 3’UTR-luciferase reporter was obtained from ORIGENE (Rockville, MD). Rabbit polyclonal antibody against 15-PGDH was purchased from Cayman chemical (Ann Arbor, MI). Rabbit polyclonal antibody against c-myc was purchased from Santa Cruz Biotechnology (Dallas, TX). Mouse monoclonal antibodies against CTDSPL and CTDSPI were purchased from Abcam (Cambridge, MA). Mouse monoclonal antibodies against β-actin were purchased from Sigma-Aldrich (St. Louis, MO). siRNA against 15-PGDH was synthesized by ORIGENE (Rockville, MD). NOD CB17-prkdc/SCID mice were purchased from Jackson lab (Bar Harbor, Maine) and maintained in Tulane transgenic mice facility according to the protocol approved by the American Association for Accreditation of Laboratory Animal Care. All primers used in this study were synthesized by Integrated DNA Technologies (IDT, Coralville, IA) (Supplementary Table 1). All chemical reagents were analytical grades (Sigma, St. Louis, MO).

Cell culture. Two human cholangiocarcinoma cell lines, CCLP1 and TFK-1, were used in this study. TFK-1 cells (37) were obtained from the Japanese Cancer Research Resources Bank where the cell line was tested and authenticated by DNA fingerprinting, isozyme detection, cell vitality assay and mycoplasma detection. Authentication of CCLP1 cells (38) was based on morphologic features, immunohistochemistry, ultrastructural analysis and cytogenetic analysis,
and the cells were cultured as we previously described (14, 17, 19). The TFK-1 and CCLP1 were maintained in RPMI-1640 and DMEM culture medium, respectively. All culture medium were supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin and streptomycin. Cells were cultured at 37°C in a humidified atmosphere containing 5% CO₂. All cell lines were used at low passage number not exceeding 30 passages.

**Stable cell lines.** CCLP1 and TFK-1 cells were transfected with Fat-1 expression plasmid or control vector pcDNA3 and then maintained in complete culture medium with 0.2 ug/ml puromycin (life technology, Grand Island, NY). CCLP1 and TFK-1 cells were also infected with miR26a/b lentivirus or miRNA-scramble control and the cells were maintained in culture medium with 0.2 mg/ml Geneticin (life technology, Grand Island, NY). Medium is replaced every 3 days for 2-4 weeks until outgrowth of resistant cells. The resistant cells were harvested and maintained in culture media with selection agents for further use.

**Gene expression analysis.** Total RNA was extracted according to TRIzol® Reagent method (life technology, Grand Island, NY). mRNA levels were quantified by using RT² SYBR® Green qPCR kit (QIAGEN, Germantown, MD); GAPDH is measured as reference gene. miRNA levels were quantified by using miScript Primer Assays kit (QIAGEN, Germantown, MD); U6 is measured as reference gene. Primers used are listed in Supplementary Table 1. For Western blotting analyses, whole cell lysate were prepared by using RIPA lysis buffer with protease inhibitor cocktail tablets (Roche Diagnostics, Indianapolis, Indiana). Cellular proteins were separated by SDS-PAGE electrophoresis and transferred onto nitrocellulose membrane (Bio-Rad,
Hercules, CA). The membrane was blocked by PBS-T (0.5% Tween 20 in PBS) containing 5% nonfat milk for 1h room temperature, and then incubated with individual primary antibodies in PBS-T containing 5% nonfat milk for 2-5h at room temperature with the dilutions specified by the manufacturers. Following three washes with PBS-T, the membranes were incubated with IRDye 680LT/IRDye 800CW secondary antibodies (LI-COR Biosciences, Lincoln, NE) in PBS-T for 1 h room temperature. The membranes were then washed with PBS-T and the protein bands were visualized by using the ODYSSEY infrared imaging system (LI-COR Biosciences, Lincoln, NE).

**Dual-Luciferase Reporter Assay.** Cells were co-transfected with luciferase reporter (15-PGDH promoter-luciferase, 15-PGDH 3’UTR-luciferase) and pRL-TK (Promega, Madison, WI). pRL-TK provides the constitutive expression of Renilla luciferase that was used as an internal control. 72h after transfection, cells were collected and passively lysed. Luciferase activities in the extracts were measured by DLReady Centro XS \(^3\) LB960 luminometer with the use of Dual-Luciferase Reporter (DLRTM) Assay kit (Promega, Madison, WI). Luciferase activity was measured against Renilla luciferase activity for transfection efficiency.

**ChIP Assay.** Cells were cross-linked by 1% formaldehyde for 10min. Chromosome DNA was extracted according to the protocol provided by SimpleChIP Assay Kits (Cell signaling, Danvers, MA) and precipitated by using specific c-myc Rabbit polyclone antibody. Rabbit polyclone antibody Histone 3 was used as positive control while Rabbit IgG was used as negative control. Regular PCR procedure (5min at 94°C, followed by 30 cycles of 30s at 94°C, 30s at 55°C, 30s at
72°C, ended by 10 min at 72°C) was adopted to amplify c-myc binding site sequence. Primers were listed in Supplementary Table 1.

**Cell proliferation assay.** 5 x 10^3 cells were plated in each well of 96-well plates and synchronized in G0 phase by serum deprivation. Growth arrest was released by adding 2% serum. WST-1 reagent (Roche Diagnostics, Indianapolis, Indiana) was used to detect cell proliferation rate according to the manufacturer’s instructions. Each point in cell growth curve represents the mean of three independent normalized OD_450_ reads.

**Colony forming Assay.** 1 x 10^3 cells were plated in 10-cm dish and allowed to grow for 14 days. The colonies were stained with crystal violet (Amersco, Solon, OH). The colonies in each dish were counted.

**TUNEL assay.** Cells (1 x 10^4 per well) were seeded in 8 well-chamber slide and cultured overnight. Then, the cells were fixed by 4% formaldehyde in PBS for 25 min. The cell apoptosis on the slide was detected according to the protocol of Deadend™ colorimetric TUNEL system (Promega, Madison, WI).

**Xenograft tumor study in SCID mice.** SCID mice were injected subcutaneously at the axillary area with indicated groups of CCLP1 cells (1 x 10^7 cells in 100μl of PBS). The mice were closely monitored for tumor growth and sacrificed 35 days post inoculation to recover the tumors. The
tumor volume was measured and calculated by using the formula: larger diameter × (smaller diameter)^2/2. RNA was extracted from recovered tumor tissues using TRIzol® Reagent (Life technology, Grand Island, NY) to measure the level of miR-26a. Proteins from the tumor tissues were extracted by using NP-40 lysis buffer for Western blotting analysis.

**Intrahepatic tumor growth via splenic injection.** General anesthesia in mice was induced by Fluriso (Vetone, BOISE, ID). The abdominal cavity was opened by a 0.5 cm left sided transverse laparotomy. The spleen was identified, and 1 × 10^6 cells (with or without 15-PGDH knockdown) in a total volume of 100µl PBS were injected into the spleen. After tumor cell inoculation, the spleen was resected and the abdominal cavity was closed by a running 3/0 braided silk suture (CP medical, Portland, OR). The mice were intraperitoneally injected with 200µl DHA (0.5mg/ml, dissolved in BSA solution) or BSA control every 2 days (starting 2 days after surgery). Five weeks after DHA treatment, the mice were sacrificed and the livers were removed to document tumor growth parameters (tumor volume was calculated by using the formula: larger diameter × [smaller diameter]²/2).

**Statistics.** Results are presented as mean ± standard error from a minimum of 3 replicates. Difference between groups was evaluated by SigmaPlot statistical software with unpaired analysis of student’s t-test and one-way analysis of variance. P<0.05 was considered as statistically significant.
RESULTS

**ω-3 PUFAs induces 15-PGDH expression in human cholangiocarcinoma cells.**

We compared the effect of ω-3 PUFA (DHA) versus ω-6 PUFA (AA) on 15-PGDH expression in human cholangiocarcinoma cell lines (CCLP1 and TFK-1). While DHA treatment increased the level of 15-PGDH protein, AA treatment exhibited no effect (**Figure 1A** and **Supplementary Figure S1**). In separate experiments, we stably transfected CCLP1 and TFK-1 cells with vector expressing the Fat-1 gene (which encodes a *C. elegans* ω-3 fatty-acid desaturase converting ω-6 to ω-3 fatty acids (39)). Overexpression of the Fat-1 gene was also found to increase 15-PGDH protein expression; the effect of Fat-1 gene transfection on 15-PGDH is comparable to DHA treatment of control cells (**Figure 1B**). Additionally, the levels of 15-PGDH mRNA were also elevated in DHA treated or Fat-1 overexpressed cells (**Figure 1C**). DHA treatment or Fat-1 expression did not alter 15-PGDH promoter activity, as reflected by the 15-PGDH promoter-luciferase assay (**Figure 1D**).

**ω-3 PUFAs suppress miR26a/b and prevent their targeting of 15-PGDH in cholangiocarcinoma cells.**

As ω-3 PUFA increased 15-PGDH protein and mRNA levels without induction of 15-PGDH promoter activity, we reasoned that ω-3 PUFA might regulate 15-PGDH gene expression through post-transcriptional mechanism. We directed out attention to microRNAs which could potentially bind to the 15-PGDH 3’UTR. Sequence analysis identified four conserved
microRNAs (miR26a, miR26b, miR1297, miR4465) that are complementary to the 15-PGDH 3’UTR (Figure 2A and Supplementary Figure S2). Among these 4 microRNAs, miR26a and miR26b were found to be highly expressed in cholangiocarcinoma cells relative to the other two (miR1297, miR4465) (Supplementary Figure S2). We next performed qRT-PCR analysis to determine whether ω-3 PUFAs might alter the expression of these miRNAs. As shown in Figure 2B and 2C, DHA treatment or Fat-1 overexpression decreased the levels of miR26a and miR26b, but not the other two miRNAs (miR1297 and miR4465). These findings suggest that ω-3 PUFA may induce 15-PGDH expression through alteration of miR26a and/or miR26b.

To further determine the effect of miR26a and miR26b on 15-PGDH, we infected human cholangiocarcinoma cells with lentivirus particles carrying miR26a (green) or miR26b gene (red) (Figure 2D); these cells were then analyzed for 15-PGDH protein expression. As shown in Figure 2E, overexpression of miR26a or miR26b significantly reduced 15-PGDH protein in both CCLP1 and TFK-1 cells and the effects were reversed by anti-miR26. We next measured the 15-PGDH 3’UTR-luciferase reporter activities in miR26a or miR26b overexpressed or control cells. As shown in Figure 2F, miR26a or miR26b overexpression decreased the 15-PGDH 3’UTR luciferase reporter activity; this effect was abolished when the miR26a/b binding sites were mutated. These results establish 15-PGDH as a direct target of miR26a/b. Accordingly, we observed that overexpression of miR26a or miR26b prevented DHA-induced 15-PGDH protein accumulation (Figure 2G).

Taken together, our findings suggest that ω-3 PUFAs induce 15-PGDH protein accumulation through suppression of miR26a/b in human cholangiocarcinoma cells.
C-myc is implicated in ω-3 PUFA-induced suppression of miR26a/b.

miR26a/b are located in the introns of CTDSPs (carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase) gene family (40, 41) (illustrated in Figure 3A). Given that the expression of miR26a/b is reported to be concomitant with their host genes (40), we measured the mRNA level of CTDSPs (CTDSPL and CTDSP1) in cholangiocarcinoma cells treated with ω-3 PUFA. Our data showed that the ω-3 PUFA DHA suppressed the expression of both CTDSPL and CTDSP1, whereas the ω-6 PUFA AA had no effect (Figure 3B). The pattern of CTDSPL and CTDSP1 alterations appears to be similar to their intronic microRNAs, suggesting that miR26a/b and their host genes are co-regulated by ω-6 PUFA in cholangiocarcinoma cells.

The expression of CTDSPs is well-known to be associated with the transcription factor c-myc. Given that c-myc is a downstream gene of Wnt signaling (42-44) and that ω-3 PUFA suppresses Wnt pathway (45, 46), we sought to further examine whether c-myc might be implicated in ω-3 PUFA-mediated suppression of CTDSPs/miR26s. Our data showed that DHA treatment decreased c-myc along with reduction of CTDSPs/miR26s (Figure 3C, 3D). Importantly, DHA-induced reduction of CTDSPs/miR26s was partially revered by overexpression of c-myc (Figure 3C, 3D). ChIP assay showed that c-myc was associated with the promoters of the CTDSPL/miR26a and CTDSP1/miR26b gene clusters (Figure 3E). These findings suggest that ω-3 PUFA regulates the expression of miR26a/b at least in part through c-myc.
Overexpression of miR26a prevents Fat-1-induced inhibition of cholangiocarcinoma growth.

To further determine the role of miR26/15-PGDH in ω-3 PUFA-induced inhibition of cholangiocarcinoma cell growth, we evaluated the growth parameters of tumor cells overexpressing Fat1 and/or miR26a. As shown in Figure 4A and 4B, overexpression of miR26a abolished Fat-1-induced inhibition of CCLP1 cell growth and colony formation, in vitro. TUNEL assay showed that Fat-1-induced CCLP1 cell apoptosis was partially reversed by miR26a overexpression (Supplementary Figure 3) (this result is consistent with our previous report that ω-3 PUFAs inhibit cholangiocarcinoma predominantly through induction of apoptosis(19)). Our further Western blotting analysis confirmed that miR26a overexpression attenuated Fat-1-induced induction of 15-PGDH (Figure 4C).

We then inoculated CCLP1 cells with or without Fat-1 and/or miR26a overexpression subcutaneously into SCID mice to monitor tumor growth in vivo. While Fat-1 expression inhibited xenograft tumor growth, overexpression of miR26a enhanced tumor growth and offset the inhibitory effect of Fat-1 (Figure 5A and 5B). Western blotting analysis using the recovered xenograft tumor tissues confirmed that miR-26a overexpression attenuated Fat-1-induced induction of 15-PGDH in vivo (Figure 5C).

Knockdown of 15-PGDH prevents ω-3 PUFA-induced inhibition of cholangiocarcinoma growth.

To further determine the role of 15-PGDH in ω-3 PUFA-induced inhibition of cholangiocarcinoma growth, we constructed cells with Fat-1 overexpressing plus 15-PGDH
knockdown. By using siRNA approach, we were able to satisfactorily reduce 15-PGDH protein in normal or Fat-1 expressed CCLP1 cells (Figure 6A). We observed that knockdown of 15-PGDH revered Fat-1-induced inhibition of CCLP1 cell proliferation and colony formation, \textit{in vitro} (Figure 6B and 6C). We next performed \textit{in vivo} experiments to evaluate the effect of \(\omega-3\) PUFAs and 15-PGDH on cholangiocarcinoma growth in SCID mice. We observed that administration of exogenous DHA to SCID mice significantly decreased tumor growth when the mice were inoculated with control vector tumor cells and that 15-PGDH knockdown reversed DHA effect \textit{in vivo} (Figure 7). These findings provide \textit{in vitro} and \textit{in vivo} evidences for an important role of 15-PGDH in \(\omega-3\) PUFA-induced inhibition of cholangiocarcinoma cell growth.
DISCUSSION

The current study provides the first evidence that ω-3 PUFAs up-regulate the expression of 15-PGDH by inhibiting miR-26a/b and that these effects contribute to ω-3 PUFA-induced inhibition of cholangiocarcinoma growth. Our findings support that ω-3 PUFA may be utilized as a non-toxic adjuvant therapeutic agent for the treatment of human cholangiocarcinoma. The significance of the study is further underscored by the fact that cholangiocarcinoma is a highly malignant human cancer currently with no effective therapy.

Previous studies have shown that ω-3 PUFAs inhibit the growth of tumor cells, while they are significantly less toxic toward normal cells (47, 48). For cells of biliary origin, we have shown that ω-3 PUFAs inhibit the growth of cholangiocarcinoma cells but not primary biliary epithelial cells (19). Thus, ω-3 PUFA may represent a non-toxic therapeutic agent for treatment of human cholangiocarcinoma. Several mechanisms for ω-3 PUFA as a cancer therapeutic agent have been documented (49). Our previous study has shown that ω-3 PUFAs inhibit cholangiocarcinoma cell growth in part through inhibition of Wnt/beta-catenin and COX-2 signaling pathways (19). The current study describes a separate novel mechanism, miR-26a/b-mediated regulation of 15-PGDH, in ω-3 PUFA-mediated inhibition of human cholangiocarcinoma. It is notable that 15-PGDH, a key enzyme that catalyzes PGE2 oxidation, is an important tumor suppressor regulated by ω-3 PUFA. Our results show that ω-3 PUFA up-regulates 15-PGDH expression in cholangiocarcinoma cells and this effect contributes to inhibition of cholangiocarcinoma growth, in vitro and in vivo.
The mechanisms for 15-PGDH-mediated inhibition of cholangiocarcinoma growth include deactivation of PGE$_2$, a pro-inflammatory and pro-tumorigenic lipid mediator which is known to promote tumor growth, invasion and angiogenesis(10). In parallel, 15-PGDH catalyzes the biotransformation of PGE$_2$ to 15-keto-PGE$_2$ which is known to activate peroxisome proliferator-activated receptor γ (PPARγ) and Smad2/3 leading to induction of TAp63 and inhibition of cholangiocarcinoma cell growth(36). It is possible that all of these mechanisms may be implicated in ω-3 PUFA-induced inhibition of cholangiocarcinoma cell growth.

Our findings present in the current study suggest that induction of 15-PGDH by ω-3 PUFA may represent an effective therapeutic target for CCA. Since the cardiovascular side effect associated with COX-2 inhibitors is largely due to inhibition of the antithrombotic prostacyclin (PGI$_2$), induction or reaction of 15-PGDH is expected to block CCA growth without inhibiting PGI$_2$ and thus incurring no significant side effect. In this context, the results presented in this study are expected to have significant impact for future management of CCA.

Another novel aspect of the current study is the illustration of miR26a/b as a key factor linking ω-3 PUFA to 15-PGDH. We show that ω-3 PUFA inhibits the expression of miR26a/b, thus leading to 15-PGDH protein accumulation. Direct targeting of 15-PGDH by miR26a/b was demonstrated by the observations that miR26a/b inhibits 15-PGDH 3’UTR luciferase reporter activity and that miR26a/b overexpression prevents ω-3 PUFA-induced 15-PGDH protein accumulation. We noted that knockdown of 15-PGDH did not reverse cholangiocarcinoma growth as potently as miR26a overexpression; this aspect may be explained by the facts that miR26s enhance Wnt/β-catenin signaling via inhibiting GSK-3β and that GSK-3β is another target of ω-3 PUFA(19, 50). Thus, the data presented in the current study, along with our previous findings, suggest that there are two targets, 15-PGDH and GSK-3β, which can be
regulated by ω-3 PUFA/miR26s in human cholangiocarcinoma cells. The interplays between PGE$_2$ and Wnt/β-catenin signaling pathways and their regulation by ω-3 PUFA are illustrated in Supplementary Figure S4.

While c-myc is a downstream oncogene of Wnt/β-catenin signaling, it is also the co-factor regulating the gene clusters formed by miR26a/b and their host CTDSPs genes(40-43). Our data presented in the current study suggest that ω-3 PUFA suppress miRNA26a and miRNA26b by inhibiting c-myc, through regulation of their host genes CTDSPs. The latter assertion is further supported by the ChIP assay showing that c-myc is associated with the promoters of the CTDSPL/miR26a and CTDSP1/miR26b gene clusters and by the observation that over-expression of c-myc prevents ω-3 PUFA-induced reduction of CTDSPs/miR26s.

In summary, the current study provides novel evidence for induction 15-PGDH by ω-3 PUFA via suppression of miR26s in human cholangiocarcinoma cells. Our findings further support the use of ω-3 PUFA as non-toxic adjuvant therapeutic agent for the treatment of human cholangiocarcinoma.
ABBREVIATIONS

15-PGDH: NAD+-dependent 15-hydroxyprostaglandin dehydrogenase
ω-3 PUFA: ω-3 polyunsaturated fatty acids
DHA: Docosahexaenoic acid
AA: Arachidonic acid
miR26s: microRNA26a and microRNA26b
CTDSPL: Carboxy-terminal domain small phosphatase-like
CTDSP1: Carboxy-terminal domain small phosphatase-1
C-MYC: Cellular Myelocytomatosis Viral Oncogene Homolog
ROS: reactive oxygen species
GSK-3β: Glycogen synthase kinase 3-β
COX-2: cyclooxygenase-2
PGE2: Prostaglandin E2
PPAR-γ: peroxisome proliferator-activated receptors-γ
PTEN: Phosphatase and tensin homolog
PKC: Protein kinase C
MEKK: MAP kinase kinase kinase
JNK: c-Jun N-terminal kinase


Yao et al. ω-3 PUFAs up-regulate the expression of 15-PGDH by inhibiting miR-26a/b

FIGURE LEGENDS

Figure 1. ω-3 PUFAs induces 15-PGDH expression in human cholangiocarcinoma cells. (A) 15-PGDH protein level increased in cholangiocarcinoma cells cultured with ω-3 PUFA DHA but not with ω-6 PUFA AA. CCLP1 or TFK-1 cells were synchronized by serum deprivation, and then maintained in serum-free medium containing 50 μM DHA or AA for 12 h; (B) 15-PGDH protein level increased in cholangiocarcinoma cells expressing Fat-1 which converts ω-6 PUFA to ω-3 PUFA. CCLP1 or TFK-1 cells stably transfected with Fat-1 expression vector or control vector were synchronization by serum deprivation. The cells were treated with or without 50 μM DHA in serum-free medium for 12 h. Total protein was analyzed by Western blotting with 15-PGDH antibody. β-actin was measured as a reference gene. (C) DHA treatment or Fat-1 gene expression increases 15-PGDH mRNA level in cholangiocarcinoma cells. 15-PGDH mRNA was measured by real-time PCR. Results were normalized to control group; the data were shown with mean±SE. *P<0.05, **P<0.01; (D) 15-PGDH promoter activity was not influenced by DHA treatment or Fat-1 expression in cholangiocarcinoma cells. CCLP1 or TFK-1 cells were co-transfected with 15-PGDH promoter-luc3 and pRL-TK plasmid which code Renilla luciferase. 72h after transfection, Luciferase activity was measured. Results were normalized to control group. Data were shown with mean±SE.

Figure 2. ω-3 PUFAs suppress miR26a/b and prevent their targeting of 15-PGDH in cholangiocarcinoma cells. (A) Putative miR26a and miR26b binding site in normal 3'-UTR or mutated 3'-UTR of 15-PGDH mRNA. (B) DHA, but not AA, decreases the levels of miR26a and...
miR26b in cholangiocarcinoma cells. CCLP1 or TFK-1 cells were synchronized by serum deprivation, and then maintained in serum-free medium containing 50 μM DHA or AA for 12 h; (C) Fat-1 expression decreased miR26a and miR26b levels in cholangiocarcinoma cells. (D) The levels of miR26a or miR26b in cholangiocarcinoma cells infected with respective lentiviral vectors. CCLP1 or TFK-1 cells were infected with miR26a or miR26b lentivirus and then subject to Geneticin selection. miR26a and miR26b were measured by real-time PCR. Results were normalized to control group. Data were shown with mean±SE. ***P<0.001. (E) miR26a or miR26b suppressed 15-PGDH expression. CCLP1 or TFK-1 cells overexpressing miR26a or miR26b were transfected with anti-miR26 or scramble control. Total protein was analyzed 72 h after transfection by Western blotting using 15-PGDH antibody. β-actin was measured as a reference gene. (F) miR26a or miR26b target 15-PGDH mRNA 3’UTR. CCLP1 and TFK-1 cells overexpressing miR26a or miR26b were transfected with 15-PGDH 3’UTR luciferase reporter vector or mutated construct. 72 hours after transfection, the cell lysates were obtained to measure luciferase activity. The results were normalized to control group and the data were presented as mean±SE. *P<0.05, ***P<0.001. (G) miR26a expression prevented ω-3 PUFA-induced 15-PGDH expression. CCLP1 and TFK-1 cells overexpressing miR26a were treated with or without 50 μM DHA for 12 h. Cellular proteins were analyzed by Western blotting using 15-PGDH antibody (β-actin was measured as a reference gene).

Figure 3. C-myc is implicated in ω-3 PUFA-induced suppression of miR26a/b. (A) Schematic representation of gene map for miR26a/b and their host gene CTDSPL and CTDSP1; (B) DHA, but not AA, decreases the mRNA levels of miR26a/b host genes CTDSPL/CTDSP1 in cholangiocarcinoma cells. CCLP1 or TFK-1 cells were synchronized by serum deprivation, and
then maintained in serum-free medium containing 50 μM DHA or AA for 12 h. CTDSPL or CTDSP1 mRNA was measured by real-time PCR. Results were normalized to control group; the data were shown with mean±SE. **P<0.01. (C) c-myc overexpression prevents DHA induced inhibition of CTDSPL and CTDSP1. CCLP1 cells infected with c-myc lentivirus or scramble control were maintained in serum free culture medium with or without 50 μM DHA for 12 h. Cellular proteins were analyzed by Western blotting with antibody against c-myc, CTDSPL and CTDSP1, respectively. β-actin were measured as reference gene. (D) c-myc overexpression prevents DHA induced inhibition of miR26a or miR26b. CCLP1 cells infected with c-myc lentivirus or scramble control were treated with or without 50 μM DHA for 12 h. The levels of miR26a and miR26b were measured by real-time PCR. Results were normalized to control group; data were shown with mean±SE. *P<0.05, **P<0.01; (E) c-myc binds to CTDSPL and CTDSP1 promoter region. Putative c-myc binding sites of CTDSPL and CTDSP1 promoter are shown. ChIP assay was performed by using antibody against c-myc to precipitate chromosome; antibody against Histone 3 was used as a positive control and Rabbit IgG as a negative control. Purified precipitating DNA was analyzed by PCR with primers amplifying c-myc binding regions in CTDSPL and CTDSP1 gene promoters.

Figure 4. Overexpression of miR26a prevents Fat-1-induced inhibition of cholangiocarcinoma growth in vitro. Different groups of CCLP1 cells (Fat-1 expression, miR26a overexpression, Fat-1/miR26a co-expression and control) were analyzed for cell proliferation by WST-1 assay and by colony formation assay. (A) Overexpression of Fat-1 inhibited CCLP1 colony forming ability; this effect was reversed by overexpression of miR-26a. Overexpression of miR26a alone was found to enhance CCLP1 colony formation efficiency.
Yao et al. \( \omega-3 \) PUFAs up-regulate the expression of 15-PGDH by inhibiting miR-26a/b

Representative of three independent experiments were showed in upper panel. Quantified results were normalized to control group and presented as mean±SE in lower panel; *P<0.05; **P<0.01; (B) Overexpression Fat-1 inhibited CCLP1 growth in vitro; this effect was reversed by miR26a overexpression. Overexpression miR26a alone significantly enhanced CCLP1 growth. The data are presented as mean±SE from 3 independent experiments. **P<0.01; (C) The levels of 15-PGDH protein in CCLP1 cells with Fat-1 overexpression, miR26a overexpression, Fat-1/miR26a co-expression, or control vector cells. Total protein was analyzed by Western blot with 15-PGDH antibody. \( \beta \)-actin were measured as a reference gene.

**Figure 5. \( \omega-3 \) PUFAs induce 15-PGDH and inhibit cholangiocarcinoma growth in vivo.**

CCLP1 cells (with Fat-1 overexpression, miR26a overexpression, Fat-1/miR26a co-expression, or control vector cells) were inoculated into SCID mice (n=6). Tumors growth was monitored and recovered 35 days later. Overexpression of Fat-1 inhibited tumor growth in vivo; this effect was reversed by overexpression of miR26a. Overexpression miR26a alone was found to enhance tumor growth in vivo. (A) Gross photograph of tumors recovered from SCID mice. (B) Bar graphs showing the average volume of recovered tumors and the average miR26a expression levels in the recovered tumors. The volume of tumor was calculated as described in the methods; the level of miR26a was measured by real-time PCR. Results were normalized to control group. Data was presented as mean mean±SE, *P<0.05, **P<0.01; (C) Representative Western blot for 15-PGDH in recovered tumor tissues. \( \beta \)-actin was measured as a reference gene.
Figure 6. Knockdown of 15-PGDH prevents Fat-1-induced inhibition of cholangiocarcinoma growth. Fat-1 overexpressed or control CCLP1 cells were transfected with 15-PGDH siRNA and the cells were evaluated for proliferation (WST-1) and colony formation. (A) The levels of 15-PGDH protein in cells with or without 15-PGDH knockdown. The cells were lysed 72 h after 15-PGDH siRNA transfection; total protein was analyzed by western blot with 15-PGDH antibody (β-actin was measured as a reference gene). (B) Knockdown 15-PGDH enhances CCLP1 cell growth and prevents Fat-1 induced inhibition of growth. The data are presented as mean±SE from 3 independent experiments. *P<0.05; **P<0.01; (C) Knockdown of 15-PGDH in CCLP1 cells prevents Fat-1 induced inhibition of colony formation. Representative of three independent experiments were showed in the left panel. Quantified results were normalized to vector control group and presented as mean±SE in the right panel; *P<0.05; **P<0.01.

Figure 7. The effect of 15-PGDH and DHA on cholangiocarcinoma growth in vivo. CCLP1 cells with or without 15-PGDH knockdown were inoculated into SCID mice via splenic injection and the animals were treated with DHA or BSA control as described in the Methods. (A) Representative gross images of the liver from each group of mice. The arrowheads denote areas of tumor growth. (B) Average tumor volume (**P<0.01; a compared to vector control group with BSA injection, b compared to vector control group with BSA injection, c compared to vector control group with BSA+DHA injection).
Figure 1

A

CCLP1

TFK-1

15-PGDH

β-actin

Control AA DHA

15-PGDH

β-actin

Control AA DHA

B

CCLP1

TFK-1

15-PGDH

β-actin

pcDNA pcDNA/DHA Fat-1

15-PGDH

β-actin

pcDNA pcDNA/DHA Fat-1

C

[Graph showing relative 15-PGDH mRNA expression for CCLP1 and TFK-1 with different treatments.]

D

[Graph showing relative 15-PGDH promoter luciferase activity for CCLP1 and TFK-1 with different treatments.]
Figure 2

A Putative miR26 target in 15-PGDH 3'UTR From 446-453

3'ucGAUAC_ggaCCUua_AUGAACUU5' miR26a
5'U_CAUUUucCaGGagaUACUUGAA3' WT 15-PGDH 3'UTR
3' uGGAUCA_gguCUua_AUGAACUU 5' miR26b

B

C

D

E

F

G

Relative normalized miRNA expression

Control
AA
DHA

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Relative normalized miRNA expression

CCLP1

TFK-1

Rela
Figure 3

A

Has-miR-26a-1-CTDSP1
 Chr3:37,903,451

miR-26a-1
 38,025,960

Has-miR-26b-CTDSP1
 Chr2:219,262,979

miR-26b
 219,270,664

B

CTDSP1

CTDSP1

Relative normalized mRNA expression

C

CCLP1

TFK-1

D

miR26a

miR26b

Relative normalized mRNA expression

E

CTDSP1

CTDSP1

Downloaded from cancerres.aacrjournals.org on June 8, 2017. © 2015 American Association for Cancer Research.
Figure 4

A

Colony Forming

LV/pcDNA3  Fat-1  LV-miR26a/Fat-1  LV-miR26a

B

Normalized Cell Count

LV/pcDNA3  Fat-1  LV-miR26a/Fat-1  LV-miR26a

C

CCLP1

miR26a

Fat-1

15-PGDH

β-actin

Downloaded from cancerres.aacrjournals.org on June 8, 2017. © 2015 American Association for Cancer Research.
Figure 5

A

LV/pcDNA3

Fat-1

LV-miR26a/Fat-1

LV-miR26a

B

Tumor Volume (mm³)

LV/pcDNA3  Fat-1  LV-miR26a/Fat-1  LV-miR26a

Normalized miR26a Expression

LV/pcDNA3  Fat-1  LV-miR26a/Fat-1  LV-miR26a

C

LV/pcDNA3  Fat-1  LV-miR26a/Fat-1  LV-miR26a

15-PGDH  β-actin
Figure 6

A

CCLP1

<table>
<thead>
<tr>
<th></th>
<th>Fat-1</th>
<th>Control siRNA</th>
<th>15-PGDH siRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

15-PGDH

β-actin

B

Normalized Cell Number

Time (d)

Fat-1/Control siRNA
pcDNA/Control siRNA
Fat-1/15-PGDH siRNA
pcDNA/15-PGDH siRNA

C

Normalized Colony Count

Fat-1
Control siRNA
15-PGDH siRNA

pcDNA3
Fat-1
Figure 7

A

<table>
<thead>
<tr>
<th>BSA Control</th>
<th>Vector Control</th>
<th>15-PGDH KO</th>
</tr>
</thead>
</table>

DHA

B

![Graph showing tumor volume comparison between BSA Control, Vector Control, and 15-PGDH KO with statistical significance markers]

Downloaded from cancerres.aacrjournals.org on June 8, 2017. © 2015 American Association for Cancer Research.
ω-3 polyunsaturated fatty acids upregulate 15-PGDH expression in cholangiocarcinoma cells by inhibiting miR-26a/b expression

Lu Yao, Chang Han, Kyoungsub Song, et al.

Cancer Res Published OnlineFirst February 17, 2015.

Updated version Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-14-2561

Supplementary Material Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2015/02/17/0008-5472.CAN-14-2561.DC1

Author Manuscript Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.